Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid

杜皮鲁玛 医学 甲基强的松龙 大疱性类天疱疮 硫唑嘌呤 内科学 类天疱疮 胃肠病学 皮肤病科 特应性皮炎 免疫学 疾病 抗体
作者
Yihua Zhang,Qiuyun Xu,Lihong Chen,Jiawen Chen,Jing Zhang,Ying Zou,Ting Gong,Chao Ji
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:12 被引量:68
标识
DOI:10.3389/fimmu.2021.738907
摘要

Background Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects. Safer treatment modalities are therefore needed. Dupilumab is a biologic agent used to treat BP in recent years. Methods Medical records of patients with moderate-to-severe BP were retrospectively reviewed. Twenty-four patients were included (follow-up period: 32 weeks), eight of whom received dupilumab in combination with methylprednisolone and azathioprine (dupilumab group) while the other 16 patients received methylprednisolone and azathioprine (conventional group). Response to dupilumab was evaluated by comparison of several parameters (time to stop new blister formation, time to reduce the systemic glucocorticoids to minimal dose, and total amount of methylprednisolone). Results The median age of patients in the dupilumab and conventional groups were 64.50 years (range: 22–90 years) and 64.50 years (range: 17–86 years), respectively. The median duration of disease before admission in the dupilumab group was 2 months (range: 1–240 months) and 2.5 months (range: 1–60 months) in the conventional group. The median time to stop new blister formation was 8 days (range: 1–13 days) and 12 days (range: 5–21 days) in patients of the dupilumab and conventional groups, respectively ( p = 0.028 by Kaplan-Meier analysis). In addition, the median time to reduce the systemic glucocorticoids to minimal dose (methylprednisolone 0.08 mg/kg/day) was 121.5 and 148.5 days for the dupilumab and conventional therapy groups, respectively ( p = 0.0053 by Kaplan-Meier analysis). The median total amount of methylprednisolone (at the time of reaching the minimal dose) used in the dupilumab group was 1,898 mg (range: 1,624–2,932 mg) while the cumulative dose of conventional group was 2,344 mg (range: 1,708–4,744 mg) ( p = 0.036 by Mann-Whitney U test). The median total amount of azathioprine (at the time of reaching the minimal dose) used in dupilumab group was 8,300 mg (range: 7,100–10,400 mg) while the total dose of conventional group was 10,300 mg (range: 8,900–14,400 mg) ( p = 0.0048 by Mann-Whitney U test). No adverse event related to dupilumab was recorded. Conclusions Dupilumab in addition to methylprednisolone and azathioprine seems superior to methylprednisolone/azathioprine alone in controlling disease progression and accelerating the tapering of glucocorticoids.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
刚刚
jhxie完成签到,获得积分10
1秒前
WN发布了新的文献求助10
1秒前
sssyq发布了新的文献求助10
1秒前
3秒前
WY发布了新的文献求助10
4秒前
5秒前
5秒前
成就山河发布了新的文献求助10
5秒前
6秒前
领导范儿应助sssyq采纳,获得10
7秒前
7秒前
落寞的书易完成签到 ,获得积分10
8秒前
大方弘文发布了新的文献求助10
8秒前
8秒前
9秒前
谦让玲发布了新的文献求助10
9秒前
奇奇淼发布了新的文献求助10
9秒前
Lucas应助小田心采纳,获得10
10秒前
顺利紫山发布了新的文献求助10
10秒前
青春完成签到 ,获得积分10
10秒前
叶叶完成签到,获得积分10
11秒前
深情安青应助靓丽的发箍采纳,获得10
13秒前
壳米应助谦让玲采纳,获得10
16秒前
20秒前
上官若男应助哈哈哈哈采纳,获得10
20秒前
孙燕应助zhao采纳,获得30
20秒前
雪山完成签到,获得积分10
20秒前
20秒前
22秒前
谦让玲完成签到,获得积分10
22秒前
无花果应助讨厌科研采纳,获得10
23秒前
25秒前
25秒前
NexusExplorer应助hanleiharry1采纳,获得10
25秒前
27秒前
28秒前
29秒前
Owen应助八九采纳,获得10
31秒前
哈哈哈哈发布了新的文献求助10
31秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989390
求助须知:如何正确求助?哪些是违规求助? 3531487
关于积分的说明 11254109
捐赠科研通 3270153
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809174